Study wrapper · #1137
Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care.
Editor's note
The neuropsychiatric question has followed semaglutide since regulators opened reviews into suicidality reports, and this study adds a reassuring data point from a population with a high baseline burden of depression. Within-person comparisons using a validated questionnaire found essentially no overall change, and the largest subgroup shift was an improvement among the most depressed. It is observational and modest in size, but it lands on the same side as most of the recent evidence: no mood-worsening signal.
Plain-language abstract
Tracking 354 people with HIV who started semaglutide, researchers found no overall worsening of depression scores; people who began with the most severe depression actually saw meaningful improvement. The study speaks to lingering questions about semaglutide and mood.